Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
Date:8/4/2009

ograms including without limitation statements regarding our ability to successfully complete development activities for bitter blockers, S6973 and other sweetness enhancers and flavor ingredients; and Senomyx's ability, or Senomyx's collaborators' ability, to successfully satisfy all pertinent regulatory requirements and continue to commercialize products incorporating Senomyx's flavor ingredients in foods and beverages when anticipated or at all. Risks that contribute to the uncertain nature of the forward-looking statements include: Senomyx is dependent on its product discovery and development collaborators for all of Senomyx's revenue; Senomyx is dependent on its current and any future product discovery and development collaborators to develop and commercialize any flavor ingredients Senomyx may discover; Senomyx may be unable to develop flavor ingredients useful for formulation into products; development activities for new flavor ingredients may not demonstrate an acceptable safety profile; Senomyx or its collaborators may be unable to obtain and maintain the regulatory approval required for flavor ingredients to be incorporated into products that are sold; even if Senomyx or its collaborators receive a regulatory approval and incorporate Senomyx flavor ingredients into products, those products may never be commercially successful; Senomyx flavor ingredients may not be useful or cost-effective for formulation into products; Senomyx's ability to compete in the flavor ingredients market may decline if Senomyx does not adequately protect its proprietary technologies; and the current economic environment may negatively impact Senomyx's ability to establish new collaborations and to maintain existing product discovery and development collaborations on current terms. These and other risks and uncertainties are described more fully in Senomyx's most recently filed SEC documents, including its Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q
'/>"/>
SOURCE Senomyx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc.
2. SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC
3. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE WACHOVIA CONSUMER GROWTH CONFERENCE
6. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
7. SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008
8. SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY
9. SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS
10. SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE
11. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 11TH ANNUAL NEEDHAM GROWTH STOCK CONFERENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- , - Results From a ... Arthritis in Seven Major Industrialized Countries , , ... say their disease, impacts their ... living with rheumatoid arthritis find shopping for gifts, ... presents most, difficult to do, ...
(Date:12/11/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today ... offering have exercised in full their option to ... at the public offering price of $24.75 per ... the size of the offering to an aggregate ... expects to receive net proceeds from the offering ...
(Date:12/11/2009)... new explanation for differences in the severity of mental illness ... the more serious the handicap. The genetic defect is situated ... the amount of copies of the GDI1 gene that is ... Journal of Human Genetics , and are the result of ... a life sciences research institute in Flanders, Belgium at the ...
(Date:12/11/2009)... -- Ambit Biosciences Corporation announced today the enrollment and ... Cancer Center of the first patient in the ACE ... fficacy) Phase 2 pivotal trial in patients with ... is a novel, orally available, potent and highly selective ... tyrosine kinase-3 (FLT3) inhibitor. The ACE study is ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... the CDC,s National ... Influenza Virus Vaccine, INDIANAPOLIS, Feb. 11 Sentry ... & Prevention (CDC),signed a contract to outsource storage and ... vaccine. Sentry will warehouse and,distribute more than 500,000 vaccine ...
... 11 Replikins Ltd. announced that the,quantitative analysis ... that the current H5N1 cycle is over. Sporadic ... high mortality characteristics,are expected to subside - until ... influenza virus strain begins., 140,000 virus protein ...
... will provide real-world clinical data on the PROMUS(TM) ... Scientific,Corporation (NYSE: BSX ) today announced that ... (PROMUS(TM), ENdeavor(R) and CYpher(R)) European,registry. The registry is ... will collect real-life clinical outcome data for Boston,Scientific,s ...
Other Biology Technology:The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 2The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 3FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
(Date:12/14/2009)... clean-burning, renewable fuel that could help wean the nation ... ozone, compared with gasoline, especially in winter, according to ... Ozone production from both gasoline and E85, a blend ... is greater in warm sunny weather than during the ... and sunlight contribute to ozone formation. But E85 produces ...
(Date:12/14/2009)... 2009If you are spending the holidays with big Uncle ... would be better off with another family, spare a ... research team from McMaster University and the University of ... species that lives in groups, members make strategic decisions ... in the current issue of Biology Letters . ...
(Date:12/14/2009)... Pa., Dec. 14 MODA Technology Partners, ... (EM), utility and product testing for the Pharmaceutical ... 3.0, the company,s third generation mobile data acquisition ... organizations to further automate their regulated manufacturing processes. ... capabilities: ,, Fully-Configurable Test Methods: ...
Breaking Biology News(10 mins):Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2RainEarth 28RNER 29 Signs Purchase Agreement with HangZhou Municipal No 3 Peoples Hospital 55716 1RainEarth 28RNER 29 Signs Purchase Agreement with HangZhou Municipal No 3 Peoples Hospital 55716 2RainEarth 28RNER 29 Signs Purchase Agreement with HangZhou Municipal No 3 Peoples Hospital 55716 3Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN 28R 29 Over Crinone 28R 29 for Progesterone Supplementation 55712 1Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN 28R 29 Over Crinone 28R 29 for Progesterone Supplementation 55712 2Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN 28R 29 Over Crinone 28R 29 for Progesterone Supplementation 55712 3CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 1CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 3
... literature on transient receptor potential (TRP) channelsion channels ... touch, olfaction, and other sensesvery little is known ... mechanisms that control their gating processes. , In ... http://jgp.rupress.org/current.shtml ), the Journal of General Physiology ...
... WASHINGTON DC, March 25, 2009 - Critically endangered hawksbill ... in the Dominican Republic after a powerful government campaign ... than 99 percent of these souvenirs have been withdrawn ... , A 2006 survey carried out by TRAFFIC ...
... southern Asia drink groundwater contaminated with arsenic. Thousands of ... of cancer each year from chronic exposure to arsenic, ... call it the biggest mass poisoning in history. , ... of the contamination in the Himalaya Mountains, where sediments ...
Other Biology News:Turtles no longer turned into souvenirs 2Stanford scientists find new solutions for the arsenic-poisoning crisis in Asia 2Stanford scientists find new solutions for the arsenic-poisoning crisis in Asia 3Stanford scientists find new solutions for the arsenic-poisoning crisis in Asia 4Stanford scientists find new solutions for the arsenic-poisoning crisis in Asia 5Stanford scientists find new solutions for the arsenic-poisoning crisis in Asia 6
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
albumin from bovine serum (BSA), BODIPY® FL conjugate...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
... (human, bovine, porcine, rat) ... receptor antagonist. This carboxy-terminal VIP ... twofold more potent than any ... Storage: ...
Biology Products: